Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18381838 | 0.86 | HPGD (0.58) | MAPTLMNAPDE7AHPGDVCAM1 | |
| SCHEMBL30610315 | 0.83 | MAPT (0.58) | MAPTLMNAHPGDVCAM1POLB | |
| SCHEMBL16430875 | 0.83 | MAPT (0.58) | MAPTLMNAHPGDVCAM1POLB | |
| SCHEMBL17085945 | 0.81 | HPGD (0.54) | MAPTLMNAHPGDVCAM1POLB | |
| SCHEMBL17080227 | 0.81 | HPGD (0.54) | MAPTLMNAHPGDVCAM1POLB | |
| SCHEMBL19984746 | 0.81 | ALDH1A1 (0.58) | MAPTLMNAPDE7AHPGDPOLB | |
| SCHEMBL30401491 | 0.81 | ALDH1A1 (0.58) | MAPTLMNAPDE7AHPGDPOLB | |
| SCHEMBL17080233 | 0.81 | HPGD (0.53) | MAPTLMNAPDE7AHPGDVCAM1 | |
| SCHEMBL17080117 | 0.81 | HPGD (0.56) | MAPTLMNAHPGDVCAM1POLB | |
| SCHEMBL17080225 | 0.80 | SLC6A2 (0.56) | MAPTLMNAHPGDVCAM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064060-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2025-02-27 | — | — | US | claimed |
| EP-4426677-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2024-09-11 | — | — | EP | claimed |
| CN-118541353-A | Bis (hetero) aryl thioether (thio) amides as fungicidal compounds | 拜耳公司 | 2024-08-23 | — | — | CN | claimed |
| WO-2023078915-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | WO | claimed |
| US-20250064060-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2025-02-27 | — | — | US | disclosed |
| US-20250042886-A1 | BIS(HETERO)ARYL THIOETHER OXADIAZINES AS FUNGICIDAL COMPOUNDS | BAYER S.A.S. (FR) | 2025-02-06 | — | — | US | disclosed |
| EP-4441049-A1 | BIS(HETERO)ARYL THIOETHER OXADIAZINES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2024-10-09 | — | — | EP | disclosed |
| EP-4426677-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118541353-A | Bis (hetero) aryl thioether (thio) amides as fungicidal compounds | 拜耳公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118317956-A | Bis (hetero) aryl thioether oxadiazines as fungicidal compounds | 拜耳公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023099445-A1 | BIS(HETERO)ARYL THIOETHER OXADIAZINES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023078915-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042886-A1 | BIS(HETERO)ARYL THIOETHER OXADIAZINES AS FUNGICIDAL COMPOUNDS | CYP4Z1, STS, HPD | MAPT 2106/4885LMNA 4792/4885PDE7A 3482/4885 |
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | MAPT 3090/4885LMNA 4700/4885PDE7A 3206/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | MAPT 3090/4885LMNA 4700/4885PDE7A 3206/4885 |
| US-20250064060-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | TST, TPMT, NAT1 | MAPT 1162/4885LMNA 4788/4885PDE7A 3827/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | MAPT 3090/4885LMNA 4700/4885PDE7A 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.